Research Grade Afasevikumab (HS856076)

Даташит Поделиться продуктом Копировать информацию

Цена(USD): $

Спецификация:

100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит

Обзор

Каталожный номер	HS856076
Описание	Research Grade Afasevikumab (HS856076) is a human monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Human
Изотип	IgG1-kappa
Система экспрессии	Mammalian Cells
Виды	Human
Клоональность	Monoclonal
Цель	CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
Уровень эндотоксинов	Please contact with the lab for this information.
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	Q16552 & Q96PD4
Форма	Liquid
Буфер хранения	0.01M PBS, pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Альтернативные названия	MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9
Фон	Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. • IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881 • The IL-17 Family of Cytokines in Health and Disease., PMID:30995505 • The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781 • Functional specialization of interleukin-17 family members., PMID:21349428 • Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067 • The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764 • The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481 • Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452 • Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228 • Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Примечание	For research use only. Not suitable for clinical or therapeutic use.

Изображения

SEC-HPLC

SEC-HPLC detection for Research Grade Afasevikumab.
Bioactivity

Detects IL17A in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Afasevikumab.

Ссылки

Даташит

Research Grade Afasevikumab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Рекомбинантные Белки

Антитела

Наборы для анализа